XENON PHARMACEUTICALS INC (XENE) Covered Calls

You can sell covered calls on XENON PHARMACEUTICALS INC to lower risk and earn monthly income. Born To Sell's covered call screener gives you customized search capabilities across all possible covered calls but here are a couple of examples for XENE (prices last updated Mon 12:15 PM ET):

XENON PHARMACEUTICALS INC (XENE) Stock Quote
Last Change Bid Ask Volume P/E Market Cap
12.03 +0.57 12.00 12.05 111K - 0.2B
Covered Calls For XENON PHARMACEUTICALS INC (XENE)
Expiration Strike Call Bid Net Debit Return
If Flat
Annualized
Return If Flat
Sep 21 12.5 0.15 11.90 1.3% 14.4%
Oct 19 12.5 0.00 12.05 0.0% 0.0%
Subscribers get access to the full covered call chain, and more features.

Want to make money with covered calls?  Sign Up For A Free Trial


Extended Business Description

Xenon Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics to treat patients with neurological disorders in Canada. The company uses Extreme Genetics, a core enabling discovery platform for the discovery of validated drug targets by studying rare human diseases with extreme traits, including diseases caused by mutations in ion channels, known as channelopathies. It clinical development pipeline includes XEN1101, a Kv7 potassium channel opener for the treatment of epilepsy comprising treatment-resistant adult and pediatric focal seizures, rare and pediatric forms of epilepsy, and other neurological disorders; and XEN901, a selective Nav1.6 sodium channel inhibitor for the treatment of epilepsy. The company also develops GDC-0310 that completed Phase I clinical trials for the treatment of pain; and XEN007, a central nervous system (CNS)-acting calcium channel blocker that directly modulates Cav2.1, which is a critical calcium channel implicated in the pathophysiology of hemiplegic migraine, a rare and debilitating neurological disorder. Xenon Pharmaceuticals Inc. has collaboration agreements with Genentech, Inc. and Merck & Co., Inc. The company was founded in 1996 and is headquartered in Burnaby, Canada.